Table 4. Dual pathway and triple therapy regimens evaluated in clinical trials
Dual pathway
  1. Rivaroxaban 15 mg OD with clopidogrel 75 mg OD
  2. Dabigatran 110* or 150 mg BID with clopidogrel 75 mg OD
  3. Warfarin with clopidogrel 75 mg OD
Triple therapy
  1. Rivaroxaban 2.5 mg BID with ASA 81 mg OD and clopidogrel 75 mg OD
  2. Warfarin (INR, 2.0-2.5) with ASA 81 mg OD and clopidogrel 75 mg OD
ASA, acetylsalicylic acid;
BID, twice daily;
INR, international normalized ratio;
OD, every day

* In the RE-DUAL PCI trial, the 110 mg BID dabigatran dose was associated with a trend to a higher risk of death or thrombotic events (11% vs 8.5%; hazard ratio, 1.30; 95% confidence interval, 0.98-1.73; P ¼ 0.07). This risk was not observed with the 150 mg BID dose (7.9% vs 7.9%; hazard ratio, 0.97; 95% confidence interval, 0.68-1.39; P ¼ 0.44). Therefore, in patients who are not at high risk of bleeding, the dabigatran 150 mg BID dose, when used in combination with clopidogrel 75 mg daily (ASA omitted), might be preferable.